Page 76 - 2021_02-Haematologica-web

P. Robach et al.
rone. Blood. 2017;130(10):1243-1246.
9. Hanudel MR, Rappaport M, Chua K, et al. Levels of the erythropoietin-responsive hormone erythroferrone in mice and humans with chronic kidney disease. Haematologica. 2018;103(4):e141-e142.
10. El Gendy FM, El-Hawy MA, Shehata AMF, Osheba HE. Erythroferrone and iron status parameters levels in pediatric patients with iron deficiency anemia. Eur J Haematol. 2018;100(4):356-360.
11.Honda H, Kobayashi Y, Onuma S, et al. Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis. PLoS One. 2016;11(3):e0151601.
12. Gagliano-Jucá T, Pencina KM, Ganz T, et al. Mechanisms responsible for reduced ery- thropoiesis during androgen deprivation therapy in men with prostate cancer. Am J Physiol Endocrinol Metab. 2018;315(6): E1185-E1193.
13. Garvican-Lewis LA, Vuong VL, Govus AD, et al. Intravenous iron does not augment the hemoglobin mass response to simulat- ed hypoxia. Med Sci Sports Exerc.
2018;50(8):1669-1678.
14. Hall R, Peeling P, Nemeth E, Bergland D,
McCluskey WTP, Stellingwerff T. Single versus split dose of iron optimizes hemo- globin mass gains at 2106 m altitude. Med Sci Sports Exerc. 2019;51(4):751-759.
15.Talbot NP, Lakhal S, Smith TG, et al. Regulation of hepcidin expression at high altitude. Blood. 2012;119(3):857-860.
16.Artuso I, Pettinato M, Nai A, et al. Transient decrease of serum iron after acute erythropoietin treatment contributes to hepcidin inhibition by ERFE in mice. Haematologica. 2019;104(3):e87-e90. Mirciov CSG, Wilkins SJ, Hung GCC, Helman SL, Anderson GJ, Frazer DM. Circulating iron levels influence the regula- tion of hepcidin following stimulated ery- thropoiesis. Haematologica. 2018;103(10): 1616-1626.
18.Coffey R, Sardo U, Kautz L, Gabayan V, Nemeth E, Ganz T. Erythroferrone is not required for the glucoregulatory and hema- tologic effects of chronic erythropoietin treatment in mice. Physiol Rep. 2018;6(19):e13890.
19. Siebenmann C, Keiser S, Robach P, Lundby C. CORP: the assessment of total hemoglo-
bin mass by carbon monoxide rebreathing.
J Appl Physiol (1985). 2017;123(3):645-654. 20.Cazzola M. A global strategy for preven- tion and detection of blood doping with erythropoietin and related drugs.
Haematologica. 2000;85(6):561-563.
21. Jelkmann W, Lundby C. Blood doping and its detection. Blood. 2011;118(9):2395-
2404.
22. Ashenden M, Gough CE, Garnham A,
Gore CJ, Sharpe K. Current markers of the Athlete Blood Passport do not flag micro- dose EPO doping. Eur J Appl Physiol. 2011;111(9):2307-2314.
23. Leuenberger N, Bulla E, Salamin O, et al. Hepcidin as a potential biomarker for blood doping. Drug Test Anal. 2017;9(7):1093- 1097.
24. Cuevas KR, Schobinger C, Gottardo E, et al. Erythroferrone as a sensitive biomarker to detect stimulation of erythropoiesis. Drug Test Anal. 2020;12(2):261-267.
25. Moretti D, Mettler S, Zeder C, et al. An intensified training schedule in recreational male runners is associated with increases in erythropoiesis and inflammation and a net reduction in plasma hepcidin. Am J Clin Nutr. 2018;108(6):1324-1333.
17.
390
haematologica | 2021; 106(2)